Skip to main content
SpringerLink
Log in

Antifungal Agents

  • Chapter
  • First Online:
Drug Interactions in Infectious Diseases

Part of the book series: Infectious Disease ((ID))

  • 1722 Accesses

Abstract

Antifungal agents are often prescribed in critically ill patients who receive many other concomitant medications. Antifungal agents have the potential to interact with a significant number of drugs. Interactions involving amphotericin B are a function of its adverse effects. The azoles primarily inhibit the biotransformation or transport of other medicines, which affects their distribution and elimination. The echinocandins have the lowest propensity to interact with other medicines. The clinical relevance of antifungal-drug interactions varies substantially. This chapter reviews the pharmacokinetic properties of antifungal agents and their clinically relevant drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308–329.

    Article  PubMed  CAS  Google Scholar 

  2. Bekersky I, Fielding RH, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002;46:834–840.

    Article  PubMed  CAS  Google Scholar 

  3. Bekersky I, Fielding RH, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002;46:828–833.

    Article  PubMed  CAS  Google Scholar 

  4. Wong-Berringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603–618.

    Article  Google Scholar 

  5. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983;8:17–42.

    Article  PubMed  CAS  Google Scholar 

  6. Wang E, Lew K, Casciano CN, et al. Interaction of common azole antifungals with p-glycoprotein. Antimicrob Agents Chemother 2002;46:160–165.

    Article  PubMed  CAS  Google Scholar 

  7. Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci 2007; 96;3226–3235.

    Article  PubMed  CAS  Google Scholar 

  8. Wacher VJ, Wu CJ, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 1995;13:129–134.

    Article  CAS  Google Scholar 

  9. Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87:1322–1330.

    Article  PubMed  CAS  Google Scholar 

  10. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(suppl 1):67–87.

    PubMed  Google Scholar 

  11. Van de Velde VJ, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996;16: 424–428.

    PubMed  Google Scholar 

  12. Barone JA, Moskovitz BL, Guarnieri J, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998;18:295–301.

    PubMed  CAS  Google Scholar 

  13. Johnson MD, Hamilton CD, Drew RH, et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003;51:453–457.

    Article  PubMed  CAS  Google Scholar 

  14. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998;42:1862–1865.

    PubMed  CAS  Google Scholar 

  15. Debruyne D, Ryckelynk JP. Clinical Pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24:10–27.

    Article  PubMed  CAS  Google Scholar 

  16. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003;36:630–637.

    Article  PubMed  CAS  Google Scholar 

  17. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole. Clin Pharmacokinet 2006;45:649–663.

    Article  PubMed  CAS  Google Scholar 

  18. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47:2788–2795.

    Article  PubMed  CAS  Google Scholar 

  19. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211–220.

    Article  PubMed  CAS  Google Scholar 

  20. Krishna G, Moton A, MaL, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958–966.

    Article  PubMed  CAS  Google Scholar 

  21. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative ­bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218–222.

    Article  Google Scholar 

  22. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50:1881–1883.

    Article  PubMed  CAS  Google Scholar 

  23. Nagappan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clinical Infect Dis 2007;45:1610–1617.

    Article  CAS  Google Scholar 

  24. Schwartz S, Milatovic D, Eckhard T. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Brit J Haematol 1997;97:663–665.

    Article  CAS  Google Scholar 

  25. Poirier JM, Cheymol G. Optimization of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998;35:461–473.

    Article  PubMed  CAS  Google Scholar 

  26. Isoherranen N, Kunze KL, Allen KE, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32:1121–1131

    Article  PubMed  CAS  Google Scholar 

  27. Kunze KL, Nelson WL, Kharasch ED, Thummel KE, Isoherranen N. stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 2006;34:583–590.

    Article  PubMed  CAS  Google Scholar 

  28. Templeton IE, Thummel KE, Kharasch ED, et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008;83:77–85.

    Article  PubMed  CAS  Google Scholar 

  29. Brammer KW, Coakley AJ, Jezequel SG, et al. The disposition and metabolism of [14C] fluconazole in humans. Drug Metab Disp 1991;19:764–767.

    CAS  Google Scholar 

  30. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Disp 2003;31:540–547.

    Article  CAS  Google Scholar 

  31. Sabo JA, Abdel-Rahman SM. Voriconazole: A new triazole antifungal. Ann Pharmacotherapy 2000;34:1032–1043.

    Article  CAS  Google Scholar 

  32. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349–355.

    Article  PubMed  CAS  Google Scholar 

  33. Lee CR. Goldstein JA. Pieper JA. Cytochrome P450 2 C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251–263.

    Article  PubMed  CAS  Google Scholar 

  34. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543–3551.

    Article  PubMed  CAS  Google Scholar 

  35. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267–271.

    Article  PubMed  CAS  Google Scholar 

  36. Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: Role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004;48:815–823.

    Article  PubMed  CAS  Google Scholar 

  37. Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Disp 2005;33:676–682.

    Article  CAS  Google Scholar 

  38. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007;27:369–388.

    Article  PubMed  CAS  Google Scholar 

  39. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002;46:739–745.

    Article  PubMed  CAS  Google Scholar 

  40. Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Disp 2000;28:1274–1278.

    CAS  Google Scholar 

  41. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005;45:1145–1152.

    Article  PubMed  CAS  Google Scholar 

  42. Joseph JM, Jain R, Danziger LH. Micafungin: A new echinocandin antifungal. Pharmacotherapy 2007;27:53–67.

    Article  PubMed  CAS  Google Scholar 

  43. Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome p450 interactions of anidulafungin. Antimicrob Agent Chemother 2009;53:1149–1156.

    Article  CAS  Google Scholar 

  44. Estes KE, Penzak SR, Calis KA, Walsh TJ. Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy 2009;29:17–30.

    Article  PubMed  CAS  Google Scholar 

  45. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of ­amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296–302.

    Article  PubMed  CAS  Google Scholar 

  46. Ringdén O, Andström E, Remberger M, et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporine. Bone Marrow Transplant 1994;14(suppl 5):S10–S14.

    PubMed  Google Scholar 

  47. June CH, Thompson CB, Kennedy MS, et al. Profound hypomagnesemia associated with the use of cyclosporine for marrow transplantation. Transplantation 1985;39:620–624.

    Article  PubMed  CAS  Google Scholar 

  48. Block ER, Bennett JE. Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother 1972;1:476–482.

    PubMed  CAS  Google Scholar 

  49. Stamm AM, Diaso RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987;83:236–242.

    Article  PubMed  CAS  Google Scholar 

  50. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126–131.

    Article  PubMed  CAS  Google Scholar 

  51. Perfect JR, Dismukes WE, Dromer F, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50: 291–322.

    Article  PubMed  Google Scholar 

  52. Viviani MA. Flucytosine—what is its future? J Antimicrob Chemother 1995;35:241–244.

    Article  PubMed  CAS  Google Scholar 

  53. Chung DK, Koenig MG. Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone. Am Rev Respir Dis 1971;103:831–841.

    PubMed  CAS  Google Scholar 

  54. Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet 1999;36:233–254.

    Article  PubMed  CAS  Google Scholar 

  55. Lange D, Pavao JH, Wu J, et al. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997;37:535–540.

    PubMed  CAS  Google Scholar 

  56. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389–430.

    Article  PubMed  CAS  Google Scholar 

  57. Omar G, Whiting PH, Hawksworth GM, et al. Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit 1997;19:436–445.

    Article  PubMed  CAS  Google Scholar 

  58. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole II. A metabolically based drug interaction: in vivo studies. Drug Metab Disp 1996;24:422–428.

    Google Scholar 

  59. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: Major effect on CYPs 2B6, 2 C9, 2 C19, and 3A. Antimicrob Agents Chemother 2009;53:541–551.

    Article  PubMed  CAS  Google Scholar 

  60. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2 C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005;28:1805–1808.

    Article  PubMed  CAS  Google Scholar 

  61. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645–653.

    Article  PubMed  CAS  Google Scholar 

  62. Wandel C, Kim RB, Kajiji S, et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999;59:3944–3948.

    PubMed  CAS  Google Scholar 

  63. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003;33(Suppl. 2):1–5.

    Article  PubMed  Google Scholar 

  64. Eytan GD, Regev R, Oren G, et al. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol Chem 1996;271:12897–12902.

    Article  PubMed  CAS  Google Scholar 

  65. Ferté J. Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 2000;267;277–294.

    Article  PubMed  Google Scholar 

  66. Purkins L, Wood N, Kleinermans D, et al. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol 2003;56:45–50.

    Article  PubMed  CAS  Google Scholar 

  67. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of Age, gender, race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51:495–502.

    Article  PubMed  CAS  Google Scholar 

  68. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49–53.

    Article  PubMed  Google Scholar 

  69. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332–341.

    Article  PubMed  CAS  Google Scholar 

  70. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58–65.

    Article  PubMed  CAS  Google Scholar 

  71. Mazzu AL, Lasseter KC, Shamblin EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391–400.

    Article  PubMed  CAS  Google Scholar 

  72. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322–329.

    Article  PubMed  CAS  Google Scholar 

  73. Olkkola KT, Ahonen J, Neuvonen PJ. The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511–516.

    PubMed  CAS  Google Scholar 

  74. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 1996;60:326–331.

    Article  PubMed  CAS  Google Scholar 

  75. Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 1996;10:314–318.

    Article  PubMed  CAS  Google Scholar 

  76. Otsuji Y, Okuyama N, Aoshima T, et al. No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Ther Drug Monit 2002;24:375–378.

    Article  PubMed  CAS  Google Scholar 

  77. Oda M, Kotegawa T, Tsutsumi K, et al. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol 2003;59:615–619.

    Article  PubMed  CAS  Google Scholar 

  78. Ahonen J, Olkkola KT, Neuvonen PJ. Lack of effect of the antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monit 1996;18:124–127.

    Article  PubMed  CAS  Google Scholar 

  79. Kivistö KT, Lamberg TS, Kantola T, et al. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62:348–354.

    Article  PubMed  Google Scholar 

  80. Luurila H, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998;54:163–166.

    Article  PubMed  CAS  Google Scholar 

  81. Park JY, Shon JH, Kim KA, et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharm 2006;26:135–142.

    Article  CAS  Google Scholar 

  82. Yasui N, Kondo T, Otani K, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol 1999;19:149–154.

    Article  PubMed  CAS  Google Scholar 

  83. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 1998;54(2):167–170.

    Article  PubMed  CAS  Google Scholar 

  84. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006;12:325–334.

    Article  PubMed  CAS  Google Scholar 

  85. Varis T, Kaukonen KM, Kivistö KT, et al. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998;64:363–368.

    Article  PubMed  CAS  Google Scholar 

  86. Lebrun-Vignes B, Corbrion Archer V, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001;51:443–450.

    Article  PubMed  CAS  Google Scholar 

  87. Varis T, Kivistö KT, Backman JT, et al. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999;85:29–32.

    Article  PubMed  CAS  Google Scholar 

  88. Varis T, Kivistö KT, Backman JT, et al. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000;68:487–494.

    Article  PubMed  CAS  Google Scholar 

  89. Varis T, Kivistö KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000;56:57–60.

    Article  PubMed  CAS  Google Scholar 

  90. Raaska K, Niemi M, Neuvonen M, et al. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 2002;72:362–369.

    Article  PubMed  CAS  Google Scholar 

  91. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997;61:410–415.

    Article  PubMed  CAS  Google Scholar 

  92. Lukkari E, Juhakoski A, Aranko K, et al. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur J Clin Pharmacol 1997;52:403–406.

    Article  PubMed  CAS  Google Scholar 

  93. Hynninen VV, Olkkola KT, Bertilsson L, et al. Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. Antimicrob Agent Chemother 2009;53;587–592.

    Article  CAS  Google Scholar 

  94. Saari TI, Grönlund J, Hagelberg NM, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 2010;66:387–397.

    Article  PubMed  CAS  Google Scholar 

  95. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997;19:609–613.

    Article  PubMed  CAS  Google Scholar 

  96. Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 1997;62:510–517.

    Article  PubMed  CAS  Google Scholar 

  97. Demkier P, Hansen LL, Brøsen K. Effect of diclofenac, disulfram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999;48:829–838.

    Article  Google Scholar 

  98. Heiskanen T, Backman JT, Neuvonen M, Kontinen VK, Neuvonen PJ, Kalso E. Itraconazole, a potent inhibitor of P-glycoprotein increases plasma concentrations of oral morphine. Acta Anaestesiol Scand 2008;52:1319–1326.

    Article  CAS  Google Scholar 

  99. Zimmerman NT, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994;46:147–150.

    Article  Google Scholar 

  100. Kanda Y, Kami M, Matsuyama T, et al. Plasma concentrations of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998;16:33–37.

    Article  PubMed  CAS  Google Scholar 

  101. Lim SG, Sawyerr AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993;7:317–321.

    Article  PubMed  CAS  Google Scholar 

  102. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998;54:159–161.

    Article  PubMed  CAS  Google Scholar 

  103. Lohinavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. Journal Clin Pharmacy Ther 2005;30:201–206.

    Article  Google Scholar 

  104. May DB, Drew RH, Yedinak KC, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509–513.

    PubMed  CAS  Google Scholar 

  105. Damle B, Hess H, Kaul S, et al. Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm Drug Disp 2002;23:59–66.

    Article  CAS  Google Scholar 

  106. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998;80:1–34.

    Article  PubMed  CAS  Google Scholar 

  107. Wensel TM, Waldrop BA, Wensel B. Pitavastatin: A New HMG-CoA Reductase Inhibitor. Ann Pharmacother 2010;44:507–514.

    Article  PubMed  CAS  Google Scholar 

  108. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565–581.

    Article  PubMed  CAS  Google Scholar 

  109. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of ­lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54–61.

    Article  PubMed  CAS  Google Scholar 

  110. Ishigam M, Uchiyama M, Kondo T, et al. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions. Pharm Res 2001;18:622–631.

    Article  PubMed  CAS  Google Scholar 

  111. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601–607.

    Article  PubMed  CAS  Google Scholar 

  112. Backman JT, Kivistö KT, Olkkola KT, et al. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998;54:53–58.

    Article  PubMed  CAS  Google Scholar 

  113. Miura M, Otani K, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica 2005;35:455–465.

    Article  PubMed  CAS  Google Scholar 

  114. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole in heart and lung transplant recipients. Ann Intern Med 1990;113:327–329.

    PubMed  CAS  Google Scholar 

  115. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998;46:271–272.

    PubMed  CAS  Google Scholar 

  116. Kuypers DR, Claes K, Evenepoel P, et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient. Transplantation 2005;79:737.

    Article  PubMed  Google Scholar 

  117. Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006;26:289–295.

    Article  PubMed  Google Scholar 

  118. Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications. Clin Pharmacol Ther 2001;70:247–254.

    Article  PubMed  CAS  Google Scholar 

  119. Daveluy A, Raignoux C, Miremont-Salamé, et al. Drug interactions between inhaled corticosteroids and enzymatic inhibitors. Eur J Clin Phamacol 2009;65:743–745.

    Article  CAS  Google Scholar 

  120. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacotherapy 1998;32:915–928.

    Article  CAS  Google Scholar 

  121. Lalovic B, Phillipis B, Risler LL et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Disp 2004;32:447–454.

    Article  CAS  Google Scholar 

  122. Lalovic B, Kharasch E, Hoffer C et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006;79:461–479.

    Article  PubMed  CAS  Google Scholar 

  123. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:S52–60.

    Article  CAS  Google Scholar 

  124. Jacobsen W, Kirchner G, Hallensleben K, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-COA-reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Disp 1999;27:173–179.

    CAS  Google Scholar 

  125. McCormick AD, McKillop D, Butters CJ, et al. ZD4522- An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 2000;40:1055.

    Google Scholar 

  126. Bonay M, Jonville-Bera AP, Diot P, et al. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Safety 1993;9:309–311.

    Article  PubMed  CAS  Google Scholar 

  127. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995;58:617–624.

    Article  PubMed  CAS  Google Scholar 

  128. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998;54:155–158.

    Article  PubMed  CAS  Google Scholar 

  129. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007;63:451–456.

    Article  PubMed  CAS  Google Scholar 

  130. de Lannoy IAM, Silverman M. The mdr-1 gene product P-glycoprotein mediates transport of the cardiac glycoside, digoxin. Biochem Biophys Res Comm 1992; 189:551–557.

    Article  PubMed  Google Scholar 

  131. de Lannoy IAM, Koren G, Klein J, et al. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol 1992;263:F613–F622.

    PubMed  Google Scholar 

  132. Burmúdez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: Case report and review of literature. J Pediatr Hematol Oncol 2005;27:389–392.

    Article  Google Scholar 

  133. Bashir H, Motl S, Metzger ML, et al. Itraconazole-enhanced chemotherapy toxicity in a patient with hodgkin lymphoma. J Pediatr Hematol Oncol 2006;28:33–35.

    PubMed  Google Scholar 

  134. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993;16:400–403.

    Article  PubMed  CAS  Google Scholar 

  135. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000;56:225–229.

    Article  PubMed  CAS  Google Scholar 

  136. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. Effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527–531.

    Article  PubMed  CAS  Google Scholar 

  137. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997;51:415–419.

    Article  PubMed  CAS  Google Scholar 

  138. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996;42:465–470.

    Article  PubMed  CAS  Google Scholar 

  139. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996;41:319–323.

    Article  PubMed  CAS  Google Scholar 

  140. Saari TI, Laine K, Bertilsson L, Neuvonen PJ Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007;63:941–949.

    Article  PubMed  CAS  Google Scholar 

  141. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacotherapy 1993;27:427–430.

    CAS  Google Scholar 

  142. Mori T, Asia Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug Interaction between calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 2009;44:371–374.

    Article  PubMed  CAS  Google Scholar 

  143. Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on disposition of phenytoin. Clin Pharmacol Ther 1991;49:420–425.

    Article  PubMed  CAS  Google Scholar 

  144. Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Phamacol 2008;64:25–30.

    Article  CAS  Google Scholar 

  145. Palkama VJ, Isohanni MH, Neuvonen PJ, et al. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 1998;87:190–194.

    PubMed  CAS  Google Scholar 

  146. Cobb MN, Desai J, Brown LS, Jr., Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998;63:655–662.

    Article  PubMed  CAS  Google Scholar 

  147. Yule SM, Walker D, Cole M, et al. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Disp 1999;27:417–421.

    CAS  Google Scholar 

  148. Wakeham K, Ratanshi RP, Watson V, Ggayi AB, Khoo S, Lalloo DG. Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. J Antimicrob Chemother 2010;65:316–319.

    Article  PubMed  CAS  Google Scholar 

  149. Hynninen VV, Olkkola KT, Leino K et al. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of S-(+)- and R-(−)-ibuprofen. Antimicrob Agents Chemother 2006;50:1967–1972.

    Article  PubMed  CAS  Google Scholar 

  150. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003;37:1032–1035.

    Article  PubMed  Google Scholar 

  151. Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc 2008;100:444–446.

    PubMed  Google Scholar 

  152. Kahri J, Valkonen M, Bäcklund T, Vuoristo M, Kivistö KT. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005;60:905–907.

    Article  PubMed  Google Scholar 

  153. Krüger HU, Schuler U, Zimmermann R, et al. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989;24:781–786.

    Article  PubMed  Google Scholar 

  154. Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and ­fluconazole in renal allograft recipients. Transplantation 1991;51:1014–1018.

    Article  PubMed  CAS  Google Scholar 

  155. Mañez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994;57:1521–1523.

    PubMed  Google Scholar 

  156. Sud K, Baljinder S, Krishna VS, et al. Unpredictable cyclosporine-fluconazole interaction in renal transplant recipients. Nephrol Dial Transplant 1999;14:1698–1703.

    Article  PubMed  CAS  Google Scholar 

  157. Mihara A, Mori T, Yamazaki R, et al. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol 2008;64:89–91.

    Article  PubMed  CAS  Google Scholar 

  158. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation 2002;27:1477–1478.

    Article  Google Scholar 

  159. Pea F, Baccarani U, Tavio M. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 2008;42:1711–1716.

    Article  PubMed  CAS  Google Scholar 

  160. Upton A, McCune JS, Kirby KA, et al. Fluconazole co-administration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13:760–764.

    Article  PubMed  CAS  Google Scholar 

  161. Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC. Effects of fluconazole and clarithromycin on rifabutin and 25-O-Desacetylrifabutin pharmacokinetics. Antimicrob Agents Chemother 2000;44:2170–2172.

    Article  PubMed  CAS  Google Scholar 

  162. Hallberg P, Marten L, Wadelius M. Possible fluconazole fentanyl interaction-a case report. Eur J Clin Pharmacol 2006;62(2):491–492.

    Article  PubMed  Google Scholar 

  163. Apseloff G, Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991;31:358–361.

    PubMed  CAS  Google Scholar 

  164. Sahai J, Gallicano K, Pakuts A, et al. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with Human Immunodeficiency Virus. J Infect Dis 1994;169:1103–1107.

    Article  PubMed  CAS  Google Scholar 

  165. Saari TI, Laine K, Leino K Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006;79:362–370.

    Article  PubMed  CAS  Google Scholar 

  166. Romero AJ, Le Pogamp P, Nilsson LG, et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients. Clin Pharmacol Ther 2002;71:226–234.

    Article  PubMed  CAS  Google Scholar 

  167. Venkataramanan R, Zang S, Gayowski T, et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091–3093.

    Article  PubMed  CAS  Google Scholar 

  168. Tintillier M, Kirch L, Goffin E, Cuvelier C, Pochet JM. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005;20:664–665.

    Article  PubMed  Google Scholar 

  169. Saari TL, Laine K, Leino K et al. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 2006;80:502–508.

    Article  PubMed  CAS  Google Scholar 

  170. Liu P, Foster G, LaBadie R et al. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother 2007;51:110–118.

    Article  PubMed  CAS  Google Scholar 

  171. Hagelberg NM, Nieminen TH, Saari TI, et al. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 2009;65:263–271.

    Article  PubMed  CAS  Google Scholar 

  172. Hynninen VV, Olkkola KT, Leino K, et al. Effect of voriconazole on the pharmacokinetics of diclofenac. Fundamental Clin Pharmacol 2007;21:651–656.

    Article  CAS  Google Scholar 

  173. Hynninen VV, Olkkola KT. Neuvonen PJ, Laine KT. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodnamics of etoricoxib. Eur J Clin Pharmacol 2009;65:89–95.

    Article  PubMed  CAS  Google Scholar 

  174. Purkins L, Wood N, Kleinermans D, et al. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;56(Suppl 1):24–29.

    Article  PubMed  CAS  Google Scholar 

  175. Purkins L, Wood N Ghahramani P, et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56(Suppl 1):37–44.

    Article  PubMed  CAS  Google Scholar 

  176. Liu P, Foster G, Labadie RR, Gutierrez MJ, Sharma A. Voriconazole and efavirenz at steady state in healthy male subjects. J Clin Phamacol 2008;48:73–84.

    CAS  Google Scholar 

  177. Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65:523–530.

    Article  PubMed  CAS  Google Scholar 

  178. Liu P, Grover F, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agent Chemother 2007;51:3617–3626.

    Article  CAS  Google Scholar 

  179. Mikus G, Schöwel V, Drzewinska M, et al. Potent cytochrome P450 2 C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126–135.

    Article  PubMed  CAS  Google Scholar 

  180. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730–1744.

    Article  PubMed  CAS  Google Scholar 

  181. von Moltke LL, Greenblatt DJ, Granda BW, et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001;41:85–91.

    Article  Google Scholar 

  182. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002;72:1–9.

    Article  PubMed  CAS  Google Scholar 

  183. Gubbins PO, Heldenbrand SD. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010;53:95–113.

    Article  PubMed  CAS  Google Scholar 

  184. Muijser RBR, Goa KL, Scott LJ. Voriconazole in the treatment of invasive aspergillosis. Drugs 2002;18:2655–2664.

    Article  Google Scholar 

  185. Alffenaar JWC, van der Elst KCM, Uges DRA, Kosterink JGW, Daenen SMGJ. Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage. Br J Clin Pharmacol 2009;68:462–463.

    Article  PubMed  CAS  Google Scholar 

  186. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of oral and intravenous midazoloam: A phase I randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009;31:286–298.

    Article  PubMed  CAS  Google Scholar 

  187. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27:825–834.

    Article  PubMed  CAS  Google Scholar 

  188. Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009;25:701–707.

    Article  PubMed  CAS  Google Scholar 

  189. Krishna G, Moton A, Ma L, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009;51:437–444.

    Article  PubMed  CAS  Google Scholar 

  190. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804–808.

    Article  PubMed  CAS  Google Scholar 

  191. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007;23:1415–1422.

    Article  PubMed  CAS  Google Scholar 

  192. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007;23:545–552.

    Article  PubMed  CAS  Google Scholar 

  193. Berge M, Chevalier P, Benammer M, et al. Safe management of tacrolimus together with posaconazole in lung transplants with cystic fibrosis. Ther Drug Monit 2009;31:396–399.

    Article  PubMed  CAS  Google Scholar 

  194. Hebert MF, Blough DK, Townsend RW et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005;45:1018–1024.

    Article  PubMed  CAS  Google Scholar 

  195. Hebert MF, Townsend RW, Austin S et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005;45:954–960.

    Article  PubMed  CAS  Google Scholar 

  196. Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004;48:4306–4314.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, 4301 West Markham, #522, 72205-7122, Little Rock, AR, USA

    Paul O. Gubbins

  2. Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA

    Jarrett R. Amsden

Authors
  1. Paul O. Gubbins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jarrett R. Amsden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul O. Gubbins .

Editor information

Editors and Affiliations

  1. , Infectious Diseases, GlaxoSmithKline, Research Triangle Park, 27709, North Carolina, USA

    Stephen C. Piscitelli

  2. College of Pharmacy, Dept. Pharmacy Practice, University of Illinois, Chicago, Chicago, 60612-7230, Illinois, USA

    Keith A. Rodvold

  3. , Pharmaceutical Sciences, Albany College of Pharmacy, Albany, 12208, New York, USA

    Manjunath P. Pai

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gubbins, P.O., Amsden, J.R. (2011). Antifungal Agents. In: Piscitelli, S., Rodvold, K., Pai, M. (eds) Drug Interactions in Infectious Diseases. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-61779-213-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-213-7_15

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-212-0

  • Online ISBN: 978-1-61779-213-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation